Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414618 | 0.94 | POLB (0.58) | POLBHTTGLACYP2D6CYP2C9 | |
| SCHEMBL2468733 | 0.94 | POLB (0.58) | POLBHTTGLACYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7389872 | 0.93 | POLB (0.57) | POLBHTTGLACYP2D6CYP2C9 | |
| SCHEMBL1554397 | 0.88 | POLB (0.60) | POLBHTTGLACYP2D6CYP2C9 | |
| SCHEMBL1554396 | 0.88 | POLB (0.60) | POLBHTTGLACYP2D6CYP2C9 | |
| SCHEMBL8393267 | 0.84 | HTT (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6686919 | 0.83 | ALDH1A1 (0.61) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL7328492 | 0.83 | ALDH1A1 (0.61) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL7327865 | 0.81 | ALDH1A1 (0.66) | POLBHTTGLACYP2D6CYP2C9 | |
| SCHEMBL7327862 | 0.81 | ALDH1A1 (0.66) | POLBHTTGLACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2010048673-A1 | MODULATION OF CELLULAR DIFFERENTIATION AND USES THEREFOR | MURDOCH CHILDRENS RESEARCH INSTITUTE (AU) | 2010-05-06 | — | — | WO | disclosed |
| US-6930115-B2 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-16 | — | — | US | disclosed |
| WO-2004062666-A2 | USE OF RHO-KINASE INHIBITORRS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | UNIVERSITY COLLEGE LONDON (GB) | 2004-07-29 | — | — | WO | disclosed |
| US-20030165576-A1 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030165576-A1 | Antitumor effect potentiators | RHOT2, ROCK2, CIT | POLB 1424/4885HTT 4707/4885GLA 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.